粪菌移植与肝癌

doi:10.3969/j.issn.1672-5069.2017.06.005

摘要/Abstract

Key words: Hepatoma, Gut microbiota, Fecal microbiota transplantation

张磊，刘超. 粪菌移植与肝癌[J]. 实用肝脏病杂志, 2017, 20(6): 658-659.

Zhang Lei，Liu Chao. Fecal microbiota transplantation in primary liver cancer[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 658-659.

[1] Rooks MG，Garrett WS. Gut microbiota，metabolites and host immunity. Nat Rev Immunol，2016，16（6）:341-352.
[2] Schroeder BO，Backhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med，2016，22（10）:1079-1089.
[3] Schwabe RF，Jobin C. The microbiome and cancer. Nat Rev Cancer，2013，13（11）:800-812.
[4] Koeth RA，Wang Z，Levison BS，et al. Intestinal microbiota metabolism of L-carnitine，a nutrient in red meat，promotes atherosclerosis. Nat Med，2013，19（5）:576-585.
[5] Zhu W，Gregory JC，Org E，et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell， 2016，165（1）:111-124.
[6] Schnabl B，Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology，2014，146（6）:1513-1524.
[7] Tao X，Wang N，Qin W. Gut microbiota and hepatocellular carcinoma. Gastrointest Tumors，2015，2（1）:33-40.
[8] Dapito DH，Mencin A，Gwak GY，et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell，2012，21（4）:504-516.
[9] Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol，2009，9（11）:799-809.
[10] Peterson LW，Artis D. Intestinal epithelial cells:regulators of barrier function and immune homeostasis. Nat Rev Immunol，2014，14（3）:141-153.
[11] Jirillo E，Caccavo D，Magrone T，et al. The role of the liver in the response to LPS:experimental and clinical findings. J Endotoxin Res，2002，8（5）:319-327.
[12] Haque TR，Barritt ASt. Intestinal microbiota in liver disease. Best Pract Res Clin Gastroenterol，2016，30（1）:133-142.
[13] Wiest R，Albillos A，Trauner M，et al. Targeting the gut-liver axis in liver disease. J Hepatol，2017，[ahead of print].
[14] Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology，2015，148（1）:30-36.
[15] Mima K，Nakagawa S，Sawayama H，et al. The microbiome and hepatobiliary-pancreatic cancers. Cancer Lett，2017，402:9-15.
[16] El-Serag HB. Hepatocellular carcinoma. N Engl J Med，2011，365（12）:1118-1127.
[17] Fatima N，Akhtar T，Sheikh N. Prebiotics:A novel approach to treat hepatocellular carcinoma. 2017，2017:6238106.
[18] Seki E，De Minicis S，Osterreicher CH，et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med，2007，13（11）:1324-1332.
[19] Yu LX，Yan HX，Liu Q，et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology，2010，52（4）:1322-1333.
[20] O'Neill LA，Golenbock D，Bowie AG. The history of Toll-like receptors-redefining innate immunity. Nat Rev Immunol，2013，13（6）:453-460.
[21] Achiwa K，Ishigami M，Ishizu Y，et al. DSS colitis promotes tumorigenesis and fibrogenesis in a choline-deficient high-fat diet-induced NASH mouse model. Biochem Biophys Res Commun， 2016，470（1）:15-21.
[22] Yu LX，Schwabe RF. The gut microbiome and liver cancer:mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol，2017，[ahead of print].
[23] Qin N，Yang F，Li A，et al. Alterations of the human gut microbiome in liver cirrhosis. Nature，2014，513（7516）:59-64.
[24] Wei X，Jiang S，Chen Y，et al. Cirrhosis related functionality characteristic of the fecal microbiota as revealed by a metaproteomic approach. BMC Gastroenterol，2016，16（1）:121.
[25] Chen Y，Ji F，Guo J，et al. Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology. Sci Rep，2016，6:34055.
[26] Bauer TM，Schwacha H，Steinbruckner B，et al. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol，2002，97（9）:2364-2370.
[27] Bajaj JS，Betrapally NS，Hylemon PB，et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology，2015，62（4）:1260-1271.
[28] Zhang HL，Yu LX，Yang W，et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J Hepatol，2012，57（4）:803-812.
[29] Hara E. Relationship between obesity，gut microbiome and hepatocellular carcinoma development. Dig Dis，2015，33（3）:346-350.
[30] Yoshimoto S，Loo TM，Atarashi K，et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature，2013，499（7456）:97-101.
[31] Zhu Q，Zou L，Jagavelu K，et al. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol，2012，56（4）:893-899.
[32] Steib CJ，Hartmann AC，v Hesler C，et al. Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis. Lab Invest，2010，90（7）:1024-1032.
[33] Lutz P，Parcina M，Bekeredjian-Ding I，et al. Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites. PLoS One，2014，9（4）:e93909.
[34] Bass NM，Mullen KD，Sanyal A，et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med，2010，362（12）:1071-1081.
[35] Smits LP，Bouter KE，de Vos WM，et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology，2013，145（5）:946-953.
[36] van Nood E，Vrieze A，Nieuwdorp M，et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med，2013，368（5）:407-415.
[37] Darnaud M，Faivre J，Moniaux N. Targeting gut flora to prevent progression of hepatocellular carcinoma. J Hepatol，2013，58（2）:385-387.
[38] Iida N，Dzutsev A，Stewart CA，et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science，2013，342（6161）:967-970.
[39] Vrieze A，Van Nood E，Holleman F，et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology，2012，143（4）:913-916.e917.
[40] Nanji AA，Khettry U，Sadrzadeh SM. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver （disease）. Proc Soc Exp Biol Med，1994，205（3）:243-247.
[41] Liu Q，Duan ZP，Ha DK，et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology，2004，39（5）:1441-1449.

粪菌移植与肝癌

Fecal microbiota transplantation in primary liver cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[2]	邢昊, 韩骏, 杨田. 应用血清PIVKA-II诊断肝细胞癌研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 934-937.
[3]	刘杏, 赵树立, 张殿隆. 七氟烷吸入时机对肝脏部分切除术患者肝脏缺血再灌注损伤的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 728-731.
[4]	张璇, 唐小云, 唐春银, 石学魁, 王惠琦, 张晓东, 沈海萍, 杨春辉. 中药方剂赤白汤对D-氨基半乳糖诱导的急性肝衰竭小鼠肠道菌群的影响研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 478-481.
[5]	裴颖, 黄峰, 殷宏振, 郭化磊. 去甲斑蝥酸钠对肝癌异位移植瘤小鼠肠道微生态的影响初探*[J]. 实用肝脏病杂志, 2019, 22(4): 486-489.
[6]	延喜胜, 李伟, 王剑. 酒精性肝病患者血清细胞因子水平和肠道菌群分布变化研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 518-521.
[7]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[8]	崔发强, 李涛, 王铮, 陈青. 原发性肝癌患者外周血KRAS基因水平及其对西妥昔单克隆抗体治疗疗效的影响[J]. 实用肝脏病杂志, 2019, 22(4): 565-568.
[9]	赵晓光, 史玉洁. 应用还原型谷胱甘肽预防处理接受TACE治疗的中晚期原发性肝癌患者对肝功能的影响[J]. 实用肝脏病杂志, 2019, 22(3): 425-428.
[10]	王明,张抒,李明,文君,郑振江. 慢性乙型肝炎患者血清与粪便HBV DNA水平对比研究[J]. 实用肝脏病杂志, 2019, 22(2): 176-179.
[11]	李克田,沈明格,王凤荣,胡春荣,曹玉杰,芦鹏. 血糖水平对原发性肝癌患者¹⁸F-FDG摄取和PET/CT检查图像质量的影响研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 256-259.
[12]	张帮健,魏寿存,杨小燕. 右美托咪啶联合丙泊酚麻醉对肝癌切除术患者围手术期血清细胞因子和术后苏醒质量的影响 ^*[J]. 实用肝脏病杂志, 2019, 22(2): 264-267.
[13]	李芳, 邹桂舟, 叶珺, 郜玉峰. 不同HBV感染转归人群外周血PD-1拷贝数分布研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 37-40.
[14]	王翠晓, 高静. 血清高尔基蛋白73、甲胎蛋白异质体3、甲胎蛋白和α-L-岩藻糖苷酶水平诊断原发性肝癌的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(1): 113-116.
[15]	陈向, 汪宝林, 吴琛, 唐劲草, 张弛, 褚朝顺. 动脉灌注化疗栓塞联合放射粒子植入治疗原发性肝癌患者疗效及其对肝组织TRF1和TRF2表达的影响^*[J]. 实用肝脏病杂志, 2019, 22(1): 121-124.